No Increase in Key Adverse Events When ART Is Started at CD4 Counts ≥350 Cells/mm3

In a large cohort study, risks for peripheral neuropathy, anemia, and renal insufficiency were higher among patients who started ART at CD4 counts <200 cells/mm³ than in those who started at CD4 counts ≥200 cells/mm³.

The optimal time to start antiretroviral therapy (ART) remains one of the major unanswered questions in the current treatment era. One of the arguments against early use of ART has been concern about earlier development of drug-related toxicities. In the absence of randomized clinical trials on this topic, data from cohort studies can provide useful clues. In the HIV Outpatient Study, investigators assessed the incidence rates of three common comorbidities — peripheral neuropathy, anemia, and renal insufficiency — among 2165 participants who were followed for at least 3 years, on average, after starting ART.

The incidence of peripheral neuropathy and renal insufficiency was significantly lower among patients who started ART at CD4 counts bet…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

No Increase in Key Adverse Events When ART Is Started at CD4 Counts ≥350 Cells/mm³

Topics

Reviewing Author